Cardiff Oncology, Inc.CRDFNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank43
3Y CAGR+7.1%
5Y CAGR-20.0%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+7.1%/yr
Annual compound
5Y CAGR
-20.0%/yr
Recent acceleration
Percentile
P43
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 13.96% |
| 2024 | -4.30% |
| 2023 | -1.05% |
| 2022 | 11.34% |
| 2021 | 44.07% |
| 2020 | 42.63% |
| 2019 | -28.04% |
| 2018 | -43.75% |
| 2017 | -38.12% |
| 2016 | 60.12% |